New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...
Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...
Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.
The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...
Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to zelasudil for treating patients with idiopathic pulmonary fibrosis, ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...